Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMYXI2V)

Drug Name
(E)-4-(3,5-dimethoxystyryl)phenol Drug Info
Synonyms
Pterostilbene; 537-42-8; 4-(3,5-Dimethoxystyryl)phenol; 3',5'-Dimethoxy-4-stilbenol; trans-pterostilbene; 4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; pterostilben; 4-[(E)-2-(3,5-dimethoxyphenyl)vinyl]phenol; UNII-26R60S6A5I; 3,5-Dimethoxy-4'-hydroxy-trans-stilbene; 3,5-Dimethoxy-4'-hydroxystilbene; 18259-15-9; trans-3,5-dimethoxy-4'-hydroxystilbene; CHEMBL83527; CHEBI:8630; VLEUZFDZJKSGMX-ONEGZZNKSA-N; 4-((E)-2-(3,5-dimethoxyphenyl)ethenyl)phenol; 26R60S6A5I; Pterostilbene, Pterocarpus; pterostilbene
Cross-matching ID
PubChem CID
5281727
ChEBI ID
CHEMBL83527
CAS Number
CAS 537-42-8
TTD Drug ID
D00AII

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Fatty acid biosynthesis -1.69 4.16e-2 16/18 (88.89%) OXSM;ACACA;FASN;...
Epithelial cell signaling in Helicobacter pylori infect... -1.70 4.27e-2 62/70 (88.57%) ATP6V0E1;ATP6V1E1;ATP6V1B2;...
Biosynthesis of unsaturated fatty acids -1.71 3.83e-2 21/27 (77.78%) TECR;FADS1;FADS2;...
Riboflavin metabolism -1.71 3.92e-2 7/8 (87.5%) ENPP1;ACP5;BLVRB
Cell cycle -1.75 2.30e-2 110/124 (88.71%) CCND1;MCM3;MCM2;...
NF-kappa B signaling pathway -1.76 2.35e-2 90/104 (86.54%) CSNK2A2;GADD45A;LCK;...
Cholesterol metabolism -1.76 2.51e-2 44/50 (88%) SCARB1;SOAT1;APOE;...
Synaptic vesicle cycle -1.76 2.83e-2 63/78 (80.77%) ATP6V0A4;SLC6A1;SLC18A3;...
Staphylococcus aureus infection -1.84 1.68e-2 72/95 (75.79%) SELP;KRT16;KRT31;...
Terpenoid backbone biosynthesis -1.91 7.54e-3 18/22 (81.82%) FDPS;IDI1;HMGCR;...
Hematopoietic cell lineage -1.91 9.05e-3 90/99 (90.91%) CD1D;CD1B;CD7;...
IL-17 signaling pathway -1.98 0.00e+0 84/94 (89.36%) JUN;IFNG;CXCL2;...
Complement and coagulation cascades -2.01 0.00e+0 76/85 (89.41%) CFHR5;C8G;SERPINC1;...
Rheumatoid arthritis -2.13 0.00e+0 78/93 (83.87%) CSF2;TGFB3;IL11;...
Steroid biosynthesis -2.22 0.00e+0 19/20 (95%) LSS;FDFT1;CYP51A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 4uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H